Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Tumor-Agnostic 1Sarcoma 1

Conditions

Gastrointestinal Neoplasms 1Colorectal Neoplasms 1

Interventions

Colonoscopy 67Blood Specimen Collection 64Standard of Care 60Exercise 59Radiosurgery 53Drug Therapy 49Radiofrequency Ablation 47Endoscopic Mucosal Resection 47Radiotherapy 45Surgical Procedures, Operative 44Methods 43Early Intervention, Educational 40Surveys and Questionnaires 39Oxaliplatin 38Laparoscopy 34Educational Status 34Fluorouracil 33Magnetic Resonance Spectroscopy 28Gemcitabine 26Biopsy 26Preoperative Exercise 25Practice Guidelines as Topic 24Control Groups 24lenvatinib 23Patient Navigation 23Electroporation 23Capecitabine 22camrelizumab 20Saline Solution 20Liver Transplantation 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase NA × fosaprepitant × Gastrointestinal × Clear all
NCT01504711 2021-04-08

Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy

Barbara Ann Karmanos Cancer Institute

Phase NA Completed
30 enrolled 12 charts
Gastrointestinal

Gastrointestinal Neoplasms

NCT01344304 2021-02-26

Study of Aprepitant / Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in Colorectal Cancer Patients - SENRI Trial

Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group

Phase NA Completed
413 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡